pCMV-T7-ABEmax(7.10)-SpG-P2A-EGFP (RTW4562) Citations (4)
Originally described in: Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.Walton RT, Christie KA, Whittaker MN, Kleinstiver BP Science. 2020 Apr 17;368(6488):290-296. doi: 10.1126/science.aba8853. Epub 2020 Mar 26. PubMed Journal
Articles Citing pCMV-T7-ABEmax(7.10)-SpG-P2A-EGFP (RTW4562)
| Articles |
|---|
Mutation-specific reporter for optimization and enrichment of prime editing.
Schene IF, Joore IP, Baijens JHL, Stevelink R, Kok G, Shehata S, Ilcken EF, Nieuwenhuis ECM, Bolhuis DP, van Rees RCM, Spelier SA, van der Doef HPJ, Beekman JM, Houwen RHJ, Nieuwenhuis EES, Fuchs SA.
Nat Commun. 2022 Mar 1;13(1):1028. doi: 10.1038/s41467-022-28656-3.
PubMed
Associated Plasmids |
| Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping. Wang P, Li H, Zhu M, Han RY, Guo S, Han R. Mol Ther Methods Clin Dev. 2022 Dec 2;28:40-50. doi: 10.1016/j.omtm.2022.11.010. eCollection 2023 Mar 9. PubMed |
| Direct measurement of engineered cancer mutations and their transcriptional phenotypes in single cells. Kim HS, Grimes SM, Chen T, Sathe A, Lau BT, Hwang GH, Bae S, Ji HP. Nat Biotechnol. 2023 Sep 11. doi: 10.1038/s41587-023-01949-8. PubMed |
| The FXR1 network acts as signaling scaffold for actomyosin remodeling. Chen X, Fansler MM, Janjos U, Ule J, Mayr C. bioRxiv [Preprint]. 2023 Nov 5:2023.11.05.565677. doi: 10.1101/2023.11.05.565677. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.